Viridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLC

Key Points

• Phase 3 topline win: Viridian’s REVEAL‑2 trial of elegrobart met its primary endpoint and management says it is "launch ready" ahead of a forthcoming PDUFA decision, driving a sharp stock rally.
• Analyst sentiment and targets: Needham reiterated a Buy rating with a $32 price target (≈70% upside), and the consensus is a "Moderate Buy" with an average target of $37.07 (13 Buys, 1 Hold, 1 Sell).
• Financials and dilution risk: Q1 results beat estimates (EPS -$0.90 vs. -$1.06; revenue +95.8% y/y), but Viridian filed for concurrent offerings totaling over $250M (≈$150M convertible notes + $100M equity/preferred), which could materially dilute shareholders.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $32.00 price target on the stock. Needham & Company LLC's price target points to a potential upside of 70.47% from the stock's current price.

Other analysts also recently issued reports about the company. Truist Financial cut their target price on Viridian Therapeutics from $36.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday, April 21st. Wall Street Zen downgraded Viridian Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. HC Wainwright cut their price objective on Viridian Therapeutics from $34.00 to $22.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. UBS Group initiated coverage on Viridian Therapeutics in a research report on Wednesday, January 7th. They set a "buy" rating and a $50.00 price objective for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $37.07.

Viridian Therapeutics Stock Up 33.5%

Shares of VRDN opened at $18.77 on Tuesday. Viridian Therapeutics has a 52-week low of $11.76 and a 52-week high of $34.29. The company has a market capitalization of $1.93 billion, a PE ratio of -5.71 and a beta of 0.82. The stock has a fifty day simple moving average of $22.03 and a two-hundred day simple moving average of $27.03. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.04 million. During the same period last year, the company earned ($0.87) EPS. The company's revenue for the quarter was up 95.8% on a year-over-year basis. As a group, equities analysts forecast that Viridian Therapeutics will post -3.79 EPS for the current year.

Institutional Trading of Viridian Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Hudson Bay Capital Management LP boosted its holdings in Viridian Therapeutics by 46.6% during the 3rd quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company's stock valued at $3,782,000 after acquiring an additional 55,689 shares during the period. Fisher Asset Management LLC boosted its holdings in Viridian Therapeutics by 135.6% during the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company's stock valued at $25,922,000 after acquiring an additional 691,267 shares during the period. Propel Bio Management LLC purchased a new position in Viridian Therapeutics during the 3rd quarter valued at about $1,942,000. Y Intercept Hong Kong Ltd boosted its holdings in Viridian Therapeutics by 430.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company's stock valued at $1,394,000 after acquiring an additional 52,414 shares during the period. Finally, Jennison Associates LLC purchased a new position in Viridian Therapeutics during the 4th quarter valued at about $35,915,000.

Viridian Therapeutics News Summary

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Positive Phase 3 topline: Viridian said its REVEAL‑2 Phase 3 trial of elegrobart in chronic thyroid eye disease met its primary endpoint and showed benefits for chronic patients, a clear clinical validation that supports regulatory and commercial prospects. Viridian eye disease drug benefits chronic patients in late-stage trial
• Positive Sentiment: PDUFA / launch readiness: Management reiterated it is “launch ready” ahead of a PDUFA target date for its TED franchise, materially raising the probability of near‑term commercialization and revenue upside if approved. PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results
• Positive Sentiment: Q1 results beat expectations: Viridian reported Q1 EPS of ($0.90), beating consensus (‑$1.06) and showing revenue growth (≈95.8% y/y, modest absolute dollars). The smaller‑than‑feared loss helped calm near‑term earnings anxiety. Viridian Therapeutics Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Trading halt / news flow: Shares were temporarily halted for “News Pending” ahead of these announcements, which amplified price moves when the results and corporate updates released. (This is a timing/market microstructure note rather than a fundamental change.)
• Negative Sentiment: Planned $250M+ concurrent offering: Viridian filed underwritten offerings for $150M of convertible senior notes plus $100M of common stock and related preferred — a material capital raise that could dilute existing shareholders and cap near‑term upside despite strengthening fundamentals. Viridian Announces Proposed Concurrent Public Offerings

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.